• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pneumonia. >Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging
【24h】

Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging

机译：对肺炎球菌的抗蛋白免疫球蛋白M反应与衰老无关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The incidence of community-acquired pneumonia and lower respiratory tract infection rises considerably in later life. Immunoglobulin M (IgM) antibody levels to pneumococcal capsular polysaccharide are known to decrease with age; however, whether levels of IgM antibody to pneumococcal proteins are subject to the same decline has not yet been investigated. Methods This study measured serum levels and binding capacity of IgM antibody specific to the pneumococcal surface protein A (PspA) and an unencapsulated pneumococcal strain in serum isolated from hospital patients aged ?60 and?≥?60, with and without lower respiratory tract infection. A group of young healthy volunteers was used as a comparator to represent adults at very low risk of pneumococcal pneumonia. IgM serum antibody levels were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry was performed to assess IgM binding capacity. Linear regression and one-way analysis of variance (ANOVA) tests were used to analyse the results. Results Levels and binding capacity of IgM antibody to PspA and the unencapsulated pneumococcal strain were unchanged with age. Conclusions These findings suggest that protein-based pneumococcal vaccines may provide protective immunity in the elderly. Trial registration The LRTI trial (LRTI and control groups) was approved by the National Health Service Research Ethics Committee in October 2013 (12/NW/0713). Recruitment opened in January 2013 and was completed in July 2013. Healthy volunteer samples were taken from the EHPC dose-ranging and reproducibility trial, approved by the same Research Ethics Committee in October 2011 (11/NW/0592). Recruitment for this study ran from October 2011 until December 2012. LRTI trial: ( NCT01861184 ), EHPC dose-ranging and reproducibility trial: ( ISRCTN85403723 ).
机译：背景社区获得性肺炎和下呼吸道感染的发生率在以后的生活中大大增加。已知肺炎球菌荚膜多糖的免疫球蛋白M（IgM）抗体水平会随着年龄的增长而降低;然而，尚未研究针对肺炎球菌蛋白的IgM抗体水平是否同样下降。方法本研究测量了≥60岁且≥60岁的住院患者（有无下呼吸道感染）中分离的血清中肺炎球菌表面蛋白A（PspA）和未封装的肺炎球菌菌株的IgM抗体的血清水平和结合能力。一组年轻的健康志愿者用作比较者，代表肺炎球菌性肺炎风险极低的成年人。通过酶联免疫吸附测定（ELISA）测量IgM血清抗体水平，并进行流式细胞术评估IgM结合能力。使用线性回归和单向方差分析（ANOVA）检验来分析结果。结果IgM抗体对PspA和未封装的肺炎球菌菌株的水平和结合能力随年龄而变化。结论这些发现表明基于蛋白质的肺炎球菌疫苗可为老年人提供保护性免疫。试验注册LRTI试验（LRTI和对照组）于2013年10月获得国家卫生服务研究伦理委员会（12 / NW / 0713）的批准。招募工作于2013年1月开始，并于2013年7月完成。健康志愿者样品取自同一研究道德委员会于2011年10月批准的EHPC剂量范围和可重复性试验（11 / NW / 0592）。该研究的招募时间为2011年10月至2012年12月。LRTI试验：（NCT01861184），EHPC剂量范围和重现性试验：（ISRCTN85403723）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号